Drugs / EM-100
last change Apr 2018 re-read 2 minutes ago

EM-100

Developed for
conjunctivitis
Investigated by
Bausch & Lomb Incorporated · ORA, Inc.

Trials 1 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03489941 Apr 2018 conjunctivitis Bausch & Lomb Incorporated Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as EM-100 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03489941
Route Other “One drop of EM-100 in either the right or left eye once on Day 1.” NCT03489941